Print

Purpose

This was a retrospective cohort study utilizing secondary data from IQVIA's open source pharmacy claims database (i.e., IQVIA LRx) selecting patients with prescription claims for ofatumumab or other DMTs of interest.

Condition

Eligibility

Eligible Ages
Between 18 Years and 99 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients with ≥ 1 prescription for ofatumumab in the LRx/Dx database were included. The date of the first observed prescription within the index window served as the index date. -. Patients with a diagnosis of COVID-19 or a COVID-19 vaccination any time during the study period. - Patients with linkage to the Dx database.

Exclusion Criteria

  • No exclusion criteria were applied to patients in the study.

Study Design

Phase
Study Type
Observational
Observational Model
Cohort
Time Perspective
Retrospective

Arm Groups

ArmDescriptionAssigned Intervention
Ofatumumab all eligible patients with at least 1 claim for ofatumumab observed during the index period were included in the ofatumumab cohort
  • Other: Ofatunumab
    All eligible patients with at least 1 claim for ofatumumab observed during the index period were included in the ofatumumab cohort
Non-ofatumumab patients with no evidence of ofatumumab during the index period were included in the non-ofatumumab cohort and included in subgroups based on the index medication: Siponimod, Ocrelizumab, Dimethyl fumarate, Glatiramer acetate

Recruiting Locations

More Details

NCT ID
NCT05576779
Status
Completed
Sponsor
Novartis Pharmaceuticals

Detailed Description

The date of first ofatumumab prescription claim or other DMT of interest was defined as the index date. No post-index requirements were imposed. Patients were linked to IQVIA's open source medical claims databases (Dx) to obtain patient clinical characteristics. The initial data were extracted in October 2020. The data and results were refreshed in April 2021 and July 2021 to allow for assessment of changes in characteristics at 6 and 9 months post-launch.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.